{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:53:44Z","timestamp":1791849224186,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276942"],"award-info":[{"award-number":["R01CA276942"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS123685"],"award-info":[{"award-number":["R21NS123685"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-19-185-01-MPC"],"award-info":[{"award-number":["RSG-19-185-01-MPC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP250557"],"award-info":[{"award-number":["RP250557"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210045"],"award-info":[{"award-number":["RP210045"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP240610"],"award-info":[{"award-number":["RP240610"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP240610"],"award-info":[{"award-number":["RP240610"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200615"],"award-info":[{"award-number":["RP200615"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP250557"],"award-info":[{"award-number":["RP250557"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["R01LM012806"],"award-info":[{"award-number":["R01LM012806"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>FDA-approved oncolytic herpes simplex virus-1 (oHSV) therapy has emerged as a promising viro-immunotherapy for solid tumors. However, tumor- and tumor microenvironment (TME)-associated adaptations following viral treatment, such as feedback immune suppression, neoangiogenesis, and enhanced tumor aggressiveness, often hinder complete tumor eradication. A deeper understanding of the molecular mechanisms underlying resistance to oHSV is crucial to enhancing its clinical impact. We recently discovered that oHSV induces Insulin-like growth factor 2 (IGF2) secretion, shaping an immunosuppressive TME. Similarly, radiotherapy (RTx) activates the IGF1\/IGF1R and YAP1 signaling pathways, further promoting therapeutic resistance. In this study, we investigated how oHSV-induced Insulin-like growth factor 1 receptor (IGF1R) signaling drives feedback pro-survival and proliferative pathways in tumor cells and evaluated the therapeutic potential of combining IGF1R blockade with oHSV and RTx. We first demonstrated that oHSV activates IGF1R signaling in vitro and in vivo, promoting tumor proliferation. While IGF1R-targeted monotherapies have shown limited cytotoxicity, its combination with oHSV led to a modest but significant increase in cytotoxicity across tested breast cancer (BC) and primary glioblastoma (GBM) cells in vitro and in vivo xenograft models. Furthermore, we observed that co-treatment with oHSV and RTx robustly activated both IGF1R and YAP1 in resistant cells, revealing the IGF1R\/YAP1 axis as a key mediator of resistance to dual oHSV and RTx therapy. Notably, the triple combination of oHSV, RTx, and IGF1R blockade yielded synergistic anti-tumor effects, abolished YAP1 expression and nuclear localization, and significantly enhanced survival in orthotopic BC and GBM models. Collectively, these findings identify the IGF1R\/YAP1 axis as a critical driver of resistance to oHSV and RTx and provide a strong rationale for the clinical evaluation of this triple-combination strategy to enhance therapeutic efficacy in patients with BC and GBM.<\/jats:p>","DOI":"10.1038\/s41419-026-09090-5","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:43:56Z","timestamp":1784267036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming IGF1R-mediated resistance to oncolytic HSV1 and radiotherapy via triple combination therapy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-0983","authenticated-orcid":false,"given":"Alexandra A.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hye","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Muk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-2411","authenticated-orcid":false,"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8598-5700","authenticated-orcid":false,"given":"Lily","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda S.","family":"Kouaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5724-2224","authenticated-orcid":false,"given":"Grace","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8582-2655","authenticated-orcid":false,"given":"Stephanie M.","family":"Bean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Mullarkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-0914","authenticated-orcid":false,"given":"Zhongming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-7791","authenticated-orcid":false,"given":"Tae Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-1111","authenticated-orcid":false,"given":"Ji Young","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"9090_CR1","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13:1383.","journal-title":"Cancers"},{"key":"9090_CR2","doi-asserted-by":"publisher","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","volume":"5","author":"J Pol","year":"2016","unstructured":"Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. OncoImmunology. 2016;5:e1115641.","journal-title":"OncoImmunology"},{"key":"9090_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630\u20139.","journal-title":"Nat Med"},{"key":"9090_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos De Matos","year":"2020","unstructured":"Lemos De Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev. 2020;17:349\u201358.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"9090_CR5","doi-asserted-by":"crossref","unstructured":"Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. Front Immunol. 2019;10:1848.","DOI":"10.3389\/fimmu.2019.01848"},{"key":"9090_CR6","doi-asserted-by":"crossref","unstructured":"Verzosa AL, McGeever LA, Bhark S-J, Delgado T, Salazar N, Sanchez EL. Herpes simplex virus 1 infection of neuronal and non-neuronal cells elicits specific innate immune responses and immune evasion mechanisms. Front Immunol. 2021;12:644664.","DOI":"10.3389\/fimmu.2021.644664"},{"key":"9090_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000841","volume":"8","author":"S Jasinski-Bergner","year":"2020","unstructured":"Jasinski-Bergner S, Mandelboim O, Seliger B. Molecular mechanisms of human herpes viruses inferring with host immune surveillance. J Immunother Cancer. 2020;8:e000841.","journal-title":"J Immunother Cancer"},{"key":"9090_CR8","doi-asserted-by":"crossref","unstructured":"Noh MH, Kang JM, Miller AA, Nguyen G, Huang M, Shim JS, et al. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. Neuro-Oncology. 2024;26:1602\u20131616.","DOI":"10.1093\/neuonc\/noae105"},{"key":"9090_CR9","doi-asserted-by":"publisher","first-page":"e11829","DOI":"10.1371\/journal.pone.0011829","volume":"5","author":"N Cheshenko","year":"2010","unstructured":"Cheshenko N, Trepanier JB, Segarra TJ, Fuller AO, Herold BC. HSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target. PLoS One. 2010;5:e11829.","journal-title":"PLoS One"},{"key":"9090_CR10","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1101\/gad.1978310","volume":"24","author":"U Chuluunbaatar","year":"2010","unstructured":"Chuluunbaatar U, Roller R, Feldman ME, Brown S, Shokat KM, Mohr I. Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. Genes Dev. 2010;24:2627\u201339.","journal-title":"Genes Dev"},{"key":"9090_CR11","first-page":"200","volume":"62","author":"A Chakravarti","year":"2002","unstructured":"Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62:200\u20137.","journal-title":"Cancer Res"},{"key":"9090_CR12","doi-asserted-by":"crossref","unstructured":"Farabaugh SM, Boone DN, Lee AV. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol. 2015;6:59.","DOI":"10.3389\/fendo.2015.00059"},{"key":"9090_CR13","doi-asserted-by":"crossref","unstructured":"Liu Z, Yang L, Wu W, Chen Z, Xie Z, Shi D, et al. Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma. Front Cell Dev Biol. 2024;12:1375030.","DOI":"10.3389\/fcell.2024.1375030"},{"key":"9090_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/bjc.2015.242","volume":"113","author":"C Maris","year":"2015","unstructured":"Maris C, D\u2019Haene N, Tr\u00e9pant AL, Le Mercier M, Sauvage S, Allard J, et al. IGF-IR: a new prognostic biomarker for human glioblastoma. Br J Cancer. 2015;113:729\u201337.","journal-title":"Br J Cancer"},{"key":"9090_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1210\/endo-127-3-1260","volume":"127","author":"I Ocrant","year":"1990","unstructured":"Ocrant I, Fay CT, Parmelee JT. Characterization of insulin-like growth factor binding proteins produced in the rat central nervous system*. Endocrinology. 1990;127:1260\u20137.","journal-title":"Endocrinology"},{"key":"9090_CR16","doi-asserted-by":"crossref","unstructured":"Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 2024;9:236.","DOI":"10.1038\/s41392-024-01937-7"},{"key":"9090_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155620","volume":"263","author":"S Kumar","year":"2024","unstructured":"Kumar S, Chaudhri S. Recent update on IGF-1\/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer. Pathol Res Pract. 2024;263:155620.","journal-title":"Pathol Res Pract"},{"key":"9090_CR18","doi-asserted-by":"crossref","unstructured":"Luo L, Zhang Z, Qiu N, Ling L, Jia X, Song Y, et al. Disruption of FOXO3a-miRNA feedback inhibition of IGF2\/IGF-1R\/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nat Commun. 2021;12:2341.","DOI":"10.1038\/s41467-021-23052-9"},{"key":"9090_CR19","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3390\/cancers14102416","volume":"14","author":"JB Vilar","year":"2022","unstructured":"Vilar JB, Christmann M, Tomicic MT. Alterations in molecular profiles affecting glioblastoma resistance to radiochemotherapy: where does the good go? Cancers. 2022;14:2416.","journal-title":"Cancers"},{"key":"9090_CR20","doi-asserted-by":"publisher","first-page":"118034","DOI":"10.1016\/j.biopha.2025.118034","volume":"187","author":"H Kheraldine","year":"2025","unstructured":"Kheraldine H, Hassan AF, Saeed S, Merhi M, Mateo JM, Ulamec M, et al. Neratinib and metformin: a novel therapeutic approach against HER2-positive breast cancer. Biomed Pharmacother. 2025;187:118034.","journal-title":"Biomed Pharmacother"},{"key":"9090_CR21","doi-asserted-by":"crossref","unstructured":"Ianza A, Sirico M, Bernocchi O, Generali D. Role of the IGF-1 axis in overcoming resistance in breast cancer. Front Cell Dev Biol. 2021;9:641449.","DOI":"10.3389\/fcell.2021.641449"},{"key":"9090_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.15252\/embj.201490784","volume":"34","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015;34:856\u201380.","journal-title":"EMBO J"},{"key":"9090_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/cvr\/cvr321","volume":"93","author":"R Troncoso","year":"2012","unstructured":"Troncoso R, Vicencio JM, Parra V, Nemchenko A, Kawashima Y, Del Campo A, et al. Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res. 2012;93:320\u20139.","journal-title":"Cardiovasc Res"},{"key":"9090_CR24","doi-asserted-by":"crossref","unstructured":"Osuka S, Zhu D, Zhang Z, Li C, Stackhouse CT, Sampetrean O, et al. N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. J Clin Invest. 2021;131:e136098.","DOI":"10.1172\/JCI136098"},{"key":"9090_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1158\/1078-0432.CCR-15-1677","volume":"22","author":"Y Ma","year":"2016","unstructured":"Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, et al. InsR\/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma. Clin Cancer Res. 2016;22:1767\u201376.","journal-title":"Clin Cancer Res"},{"key":"9090_CR26","doi-asserted-by":"publisher","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","volume":"15","author":"A Malyutina","year":"2019","unstructured":"Malyutina A, Majumder MM, Wang W, Pessia A, Heckman CA, Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLOS Comput Biol. 2019;15:e1006752.","journal-title":"PLOS Comput Biol"},{"key":"9090_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinforma"},{"key":"9090_CR28","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.bbamcr.2011.06.002","volume":"1813","author":"G Tzivion","year":"2011","unstructured":"Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta Mol Cell Res. 2011;1813:1938\u201345.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"9090_CR29","doi-asserted-by":"publisher","first-page":"98495","DOI":"10.18632\/oncotarget.21913","volume":"8","author":"D Andrade","year":"2017","unstructured":"Andrade D, Mehta M, Griffith J, Panneerselvam J, Srivastava A, Kim T-D, et al. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget. 2017;8:98495\u2013508.","journal-title":"Oncotarget"},{"key":"9090_CR30","doi-asserted-by":"crossref","unstructured":"La Verde G, Artiola V, Pugliese M, La Commara M, Arrichiello C, Muto P, et al. Radiation therapy affects YAP expression and intracellular localization by modulating lamin A\/C levels in breast cancer. Front Bioeng Biotechnol. 2022;10:969004.","DOI":"10.3389\/fbioe.2022.969004"},{"key":"9090_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-01897-8","volume":"40","author":"M Zhao","year":"2021","unstructured":"Zhao M, Zhang Y, Jiang Y, Wang K, Wang X, Zhou D, et al. YAP promotes autophagy and progression of gliomas via upregulating HMGB1. J Exp Clin Cancer Res. 2021;40:1.","journal-title":"J Exp Clin Cancer Res"},{"key":"9090_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"9090_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623:157\u201366.","journal-title":"Nature"},{"key":"9090_CR34","doi-asserted-by":"publisher","first-page":"11711","DOI":"10.1007\/s13277-016-5176-x","volume":"37","author":"M Motallebnezhad","year":"2016","unstructured":"Motallebnezhad M, Aghebati-Maleki L, Jadidi-Niaragh F, Nickho H, Samadi-Kafil H, Shamsasenjan K, et al. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. Tumor Biol. 2016;37:11711\u201321.","journal-title":"Tumor Biol"},{"key":"9090_CR35","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361.","journal-title":"N Engl J Med"},{"key":"9090_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352.","journal-title":"N Engl J Med"},{"key":"9090_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.eprac.2025.01.012","volume":"31","author":"W Huang","year":"2025","unstructured":"Huang W, Ou X, Lin S, Lin W, Chen G, Huang H, et al. Efficacy and safety of teprotumumab in thyroid eye disease: a systematic review and meta-analysis. Endocr Pract. 2025;31:640\u20139.","journal-title":"Endocr Pract"},{"key":"9090_CR38","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2217\/fon-2022-0440","volume":"18","author":"UM Lauer","year":"2022","unstructured":"Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol. 2022;18:2713\u201332.","journal-title":"Future Oncol"},{"key":"9090_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","volume":"70","author":"C Groeneveldt","year":"2023","unstructured":"Groeneveldt C, Van Den Ende J, Van Montfoort N. Preexisting immunity: barrier or bridge to effective oncolytic virus therapy? Cytokine Growth Factor Rev. 2023;70:1\u201312.","journal-title":"Cytokine Growth Factor Rev"},{"key":"9090_CR40","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373\u20139.","journal-title":"Cancer Sci"},{"key":"9090_CR41","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1038\/s41388-021-01878-3","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang Y, Zhou D, Wang K, Wang X, Wang X, et al. Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 2021;40:4580\u201391.","journal-title":"Oncogene"},{"key":"9090_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s43018-020-00150-z","volume":"2","author":"M Castellan","year":"2020","unstructured":"Castellan M, Guarnieri A, Fujimura A, Zanconato F, Battilana G, Panciera T, et al. Single-cell analyses reveal YAP\/TAZ as regulators of stemness and cell plasticity in glioblastoma. Nat Cancer. 2020;2:174\u201388.","journal-title":"Nat Cancer"},{"key":"9090_CR43","doi-asserted-by":"crossref","unstructured":"Taylor J, Dubois F, Bergot E, Levallet G. Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung. Int J Oncol. 2024;65:68.","DOI":"10.3892\/ijo.2024.5656"},{"key":"9090_CR44","doi-asserted-by":"crossref","unstructured":"Xu F, Li Z, Guan H, Ma J. YAP\/TAZ-Hippo pathway mediates the tumorigenesis of various cancers through post-translational modification represented by ubiquitination. Cell Death Discov. 2025;11:41.","DOI":"10.1038\/s41420-025-02319-w"},{"key":"9090_CR45","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/cas.15636","volume":"114","author":"J Yang","year":"2023","unstructured":"Yang J, Wu X, Wang J, Guo X, Chen J, Yang X, et al. Feedforward loop between IMP1 and YAP\/TAZ promotes tumorigenesis and malignant progression in glioblastoma. Cancer Sci. 2023;114:2053\u201362.","journal-title":"Cancer Sci"},{"key":"9090_CR46","doi-asserted-by":"crossref","unstructured":"Chan Y-T, Lin R-J, Wang Y-H, Hung T-H, Huang Y, Yu J, et al. The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells. Cell Commun Signal. 2023;21:81.","DOI":"10.1186\/s12964-023-01088-2"},{"key":"9090_CR47","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/cells9041010","volume":"9","author":"DC Rigiracciolo","year":"2020","unstructured":"Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, et al. IGF-1\/IGF-1R\/FAK\/YAP transduction signaling prompts growth effects in triple-negative breast cancer (TNBC) cells. Cells. 2020;9:1010.","journal-title":"Cells"},{"key":"9090_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00906-1","volume":"13","author":"X Zhou","year":"2020","unstructured":"Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13:1.","journal-title":"J Hematol Oncol"},{"key":"9090_CR49","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/onc.2011.379","volume":"31","author":"A Fernandez-L","year":"2012","unstructured":"Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2012;31:1923\u201337.","journal-title":"Oncogene"},{"key":"9090_CR50","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-20-0018","volume":"27","author":"K Vigneswaran","year":"2021","unstructured":"Vigneswaran K, Boyd NH, Oh S-Y, Lallani S, Boucher A, Neill SG, et al. YAP\/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma. Clin Cancer Res. 2021;27:1553\u201369.","journal-title":"Clin Cancer Res"},{"key":"9090_CR51","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/cells9081761","volume":"9","author":"EH Kim","year":"2020","unstructured":"Kim EH, Sohn BH, Eun Y-G, Lee DJ, Yim SY, Kang S-G, et al. Silence of hippo pathway associates with pro-tumoral immunosuppression: potential therapeutic target of glioblastomas. Cells. 2020;9:1761.","journal-title":"Cells"},{"key":"9090_CR52","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3390\/biomedicines9121949","volume":"9","author":"D Matthaios","year":"2021","unstructured":"Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M. YAP\/hippo pathway and cancer immunity: it takes two to tango. Biomedicines. 2021;9:1949.","journal-title":"Biomedicines"},{"key":"9090_CR53","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/cancers14030600","volume":"14","author":"F Fabro","year":"2022","unstructured":"Fabro F, Lamfers MLM, Leenstra S. Advancements, challenges, and future directions in tackling glioblastoma resistance to small kinase inhibitors. Cancers. 2022;14:600.","journal-title":"Cancers"},{"key":"9090_CR54","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cas.15587","volume":"114","author":"ST Wei","year":"2023","unstructured":"Wei ST, Chiang JY, Wang HL, Lei FJ, Huang YC, Wang CC, et al. Hypoxia-induced CXC chemokine ligand 14 expression drives protumorigenic effects through activation of insulin-like growth factor-1 receptor signaling in glioblastoma. Cancer Sci. 2023;114:174\u201386.","journal-title":"Cancer Sci"},{"key":"9090_CR55","doi-asserted-by":"crossref","unstructured":"Jurga AM, Paleczna M, Kuter KZ. Overview of general and discriminating markers of differential microglia phenotypes. Front Cell Neurosci. 2020;14:198.","DOI":"10.3389\/fncel.2020.00198"},{"key":"9090_CR56","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/2159-8290.CD-17-1124","volume":"8","author":"X Ni","year":"2018","unstructured":"Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z, et al. YAP is essential for treg-mediated suppression of antitumor immunity. Cancer Discov. 2018;8:1026\u201343.","journal-title":"Cancer Discov"},{"key":"9090_CR57","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs SA, Kov\u00e1cs T, L\u00e1nczky A, Pa\u00e1l \u00c1, Heged\u0171s ZI, Sayour NV, et al. Unlocking the power of immune checkpoint inhibitors: targeting YAP1 reduces anti-PD1 resistance in skin cutaneous melanoma. Br J Pharmacol. 2025;182:3903\u201322.","DOI":"10.1111\/bph.70052"},{"key":"9090_CR58","doi-asserted-by":"publisher","first-page":"e3000591","DOI":"10.1371\/journal.pbio.3000591","volume":"18","author":"E Stampouloglou","year":"2020","unstructured":"Stampouloglou E, Cheng N, Federico A, Slaby E, Monti S, Szeto GL, et al. Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLOS Biol. 2020;18:e3000591.","journal-title":"PLOS Biol"},{"key":"9090_CR59","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-24-0594","volume":"24","author":"I Kaushik","year":"2025","unstructured":"Kaushik I, Rajan R, Gaikwad S, Eltokhy MA, Srivastava SK. Moxidectin unravels the role of the hippo\u2013YAP pathway in maintaining immunity of glioblastoma multiforme. Mol Cancer Ther. 2025;24:1156\u201370.","journal-title":"Mol Cancer Ther"},{"key":"9090_CR60","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzm\u00e1n","year":"2014","unstructured":"Guzm\u00e1n C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One. 2014;9:e92444.","journal-title":"PLoS One"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09090-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09090-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09090-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:21:05Z","timestamp":1791847265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09090-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9090"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09090-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"881"}}